The DOI matches its Crossref record; 136 of the 172 references it cites were found in a registry or an index.
Mutational spectrum of p53 mutations in primary breast and ovarian tumors
Abstract
Breast and ovarian cancers, like other cancers, occur due to genetic damage. Research aimed to determine the specific genes involved in the development of breast and ovarian cancers will help to understand how normal breast and ovarian epithelial cells escape regulation of proliferation, apoptosis and senescence. It was determined that approximately 10% of ovarian cancers and 20-30% of breast cancers arise in women who have inherited mutations in cancer susceptibility genes such as BRCA1, BRCA2 and other DNA repair genes. The ability to perform genetic testing permits the identification of women at increased risk who can then be offered preventive strategies. The vast majority of ovarian and breast cancers are sporadic, presumably resulting from the accumulation of genetic damage over lifetime. Several genes involved in breast and ovarian carcinogenesis have been identified, most notably the p53 tumor suppressor. The recent availability of expression microarrays has facilitated the simultaneous screening of thousands of genes and this will extend further the understanding of molecular events involved in the dynamic development of ovarian and breast cancers. Then, all this knowledge could be translated into effective screening, surveillance, prevention, and treatment strategies in the future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unfortunately, p53 mutations are prevalent in numerous cancers, with up to 50% of malignancies harboring p53 mutations.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [502]
In the citing paper
“Due to the absence of a typical drug target, no approved p53-based therapies exist globally.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [502]
Citations
Cites
1 retracted
p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
Shao, Z. M., Wu, J., Shen, Z., & Nguyen, M. (2001) · PubMed · Cited by 64
Retractedp53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Landis, S., Murray, T., Bolden, S., & Wingo, P. A. (1999) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.8 · Cited by 3,068
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,065
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
Fitzgibbons, P. L., Page, D., Weaver, D. L., Thor, A. D., Allred, D. C., Gm, C., Sg, R., O’Malley, F. P., Jf, S., Connolly, J., et al. (2000) · PubMed · doi:10.5858/2000-124-0966-pfibc · Cited by 1,016
Research works printed but not linked: 2
- Takahashi, 2000, Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers, Int J Cancer, 89, 92, 10.1002/(SICI)1097-0215(20000120)89:1<92::AID-IJC15>3.0.CO;2-8 · DOI
- HK. Annual report on the results of treatment in gynecological cancer. Vol. 18. Stokholm: FIGO; 1982.
Cited by
Sorted by citations
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szállási, Z., Li, Q., Birkbak, N. J., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 982
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y.-G., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 663
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
Metadata
- Authors
- Feki, A., & Irminger-Finger, I.
- Venue
- Critical Reviews in Oncology/Hematology
- Publisher
- Elsevier BV
- Published
- 2004-11
- Volume
- 52
- Issue
- 2
- Pages
- 103-116
- ISSN
- 1040-8428 (ISSN-L)
- OpenAlex
- W2071475683
- Cited by
- 139
- References
- 172
- Citations by year
- 2025: 5 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 7 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 9 · 2016: 4 · 2015: 13 · 2014: 7 · 2013: 12 · 2012: 9
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Critical Reviews in Oncology/Hematology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- TP53 mutation, mutation spectrum, breast cancer, ovarian cancer, tumor suppressor, BRCA1, BRCA2, hereditary cancer predisposition, sporadic cancer, carcinogenesis, DNA repair genes, genetic testing, cancer prevention
- MeSH terms
- Breast Neoplasms, Family Health, Female, Gene Frequency, Humans, Mutation, Ovarian Neoplasms, Prognosis, Tumor Suppressor Protein p53
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
